U.S. Pharmaceutical Tariffs Expand to Generic Drugs: What Manufacturers Need to Know

When Prescription Analytics first examined pharmaceutical tariff policy in 2025, no pharma-specific framework had been finalized. Since then, the policy has advanced, with a branded drug framework now established and a future tariff schedule announced for imported generic drugs.

For pharmaceutical manufacturers, these developments introduce new supply chain, financial, and commercial planning considerations.

Branded Pharmaceutical Tariffs Move Forward

The branded drug tariff framework was announced in September 2025 and formally issued in April 2026.

The framework establishes a baseline 100% tariff on covered imported patented drugs, active pharmaceutical ingredients and certain key starting materials. Potential relief may be available through approved U.S. manufacturing investments, Most-Favored-Nation pricing agreements, country-specific trade arrangements and certain product exemptions.

Earlier policy discussions contemplated pharmaceutical tariffs as high as 200% more broadly. The resulting framework takes a more differentiated approach based on the manufacturer, product, source country and applicable agreement.

The inclusion of APIs and certain key starting materials is particularly important. Manufacturers with U.S. finished-dose operations may still have tariff exposure through foreign ingredient suppliers.

Generic Drug Tariff Framework Begin to Take Shape

On July 21, 2026, the administration announced the following schedule for imported generic drugs:

• 0% through July 2028
• 100% beginning August 2028
• 200% beginning August 2029

Detailed implementation requirements have not yet been released. Key questions include whether the tariffs will apply only to imported finished drugs or also to APIs and other ingredients, what U.S. investment may qualify for relief, and whether exemptions or lower-rate arrangements will be available.

These questions are particularly important for generic manufacturers, where product economics, competitive dynamics and pricing flexibility may differ significantly from those of branded products.

It’s also important to note that this may not affect the 27 member countries of the EU as the European commission expects its generic medicines will be exempt because of the US and EU zero tariff trade deal agreed upon last year.

U.S Manufacturing Incentives Are Expanding

The FDA is introducing regulatory incentives intended to support domestic pharmaceutical production, including earlier engagement for selected U.S. facility projects and priority ANDA review opportunities for qualifying domestically manufactured generic products.

These programs may improve regulatory predictability while providing additional support as manufacturers navigate the time, investment, technology transfer and validation involved in establishing new U.S. manufacturing capacity.

What Manufacturer Can Do Now

Manufacturers can begin preparing by mapping finished-product, API and ingredient exposure by product and country, modeling potential tariff and gross-to-net scenarios, reviewing supplier and customer contracts, and evaluating U.S. manufacturing or domestic CDMO options.

Cross-functional coordination among supply chain, trade, regulatory, finance, government pricing and commercial teams will also be important as additional guidance becomes available.

What Comes Next

The generic drug announcement remains less developed than the branded tariff framework. Manufacturers should continue monitoring guidance on product and ingredient scope, exemptions, investment requirements and implementation while evaluating potential impacts across their portfolios.

At Prescription Analytics, we help pharmaceutical manufacturers assess how regulatory and pricing developments may affect government pricing, rebates, gross-to-net and commercial forecasting. Contact us to learn how we can support your team in navigating the evolving U.S. pharmaceutical tariff environment.